Temporal and geographic variation in the systemic treatment of advanced prostate cancer
Abstract Background Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to characterize variation in use of the six “focus drugs” (docetaxel, abiraterone, enzalutamide, sipuleucel-T, radium-223, and cab...
Main Authors: | Megan E. V. Caram, Jason P. Estes, Jennifer J. Griggs, Paul Lin, Bhramar Mukherjee |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4166-3 |
Similar Items
-
Health care delivery system contributions to management of newly diagnosed prostate cancer
by: Noah Krampe, et al.
Published: (2023-08-01) -
Geographic variation in hospital costs, payments, and length of stay for opioid-related hospital visits in the USA
by: Mallow PJ, et al.
Published: (2018-12-01) -
Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence
by: Paramita Dasgupta, et al.
Published: (2019-04-01) -
Prostate cancer risk by occupation in the Occupational Disease Surveillance System (ODSS) in Ontario, Canada
by: Jeavana Sritharan, et al.
Published: (2019-05-01) -
Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer
by: John S. Witte, et al.
Published: (2010-10-01)